SciELO - Scientific Electronic Library Online

 
vol.31 número5Inequidades en salud: análisis sociodemográfico y espacial del cáncer de mama en mujeres de Córdoba, ArgentinaDetección de violencia del compañero íntimo en atención primaria de salud y sus factores asociados índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Gaceta Sanitaria

versión impresa ISSN 0213-9111

Resumen

SANZ-GUINEA, Aitor et al. Efficiency of “Prescribe Vida Saludable”, a health promotion innovation. Pilot phase. Gac Sanit [online]. 2017, vol.31, n.5, pp.404-409. ISSN 0213-9111.  http://dx.doi.org/10.1016/j.gaceta.2016.11.010.

Objective:

“Prescribe Vida Saludable” (PVS) is an organisational innovation designed to optimise the promotion of multiple healthy habits in primary healthcare. It aims to estimate the cost effectiveness and cost-utility of prescribing physical activity in the pilot phase of the PVS programme, compared to the routine clinical practice of promoting physical activity in primary healthcare.

Methods:

An economic evaluation of the quasi-experimental pilot phase of PVS was carried out. In the four control centres, a systematic sample was selected of 194 patients who visited the centre in a single year and who did not comply with physical activity recommendations. In the four intervention centres, 122 patients who received their first physical activity prescription were consecutively enrolled. The costs were evaluated from the perspective of the PVS programme using bottom-up methodology. The effectiveness (proportion of patients who changed their physical activity) as well as the utility were evaluated at baseline and after 3 months. The incremental cost-utility ratio (ICUR) and the incremental cost-effectiveness ratio (ICER) were calculated and a sensitivity analysis was performed with bootstrapping and 1,000 replications.

Results:

Information was obtained from 35% of control cases and 62% of intervention cases. The ICUR was €1,234.66/Quality Adjusted Life Years (QALY) and the ICER was €4.12. In 98.3% of the simulations, the ICUR was below the €30,000/QALY threshold.

Conclusions:

The prescription of physical activity was demonstrably within acceptable cost-utility limits in the pilot PVS phase, even from a conservative perspective.

Palabras clave : Cost-benefit analysis; Motor activity; Quality-adjusted life years; Primary healthcare.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )